Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Preferred Stock Liabilities: 2023-2024

  • Contineum Therapeutics' Preferred Stock Liabilities was N/A to $192.6 million in Q1 2024 from the same period last year, while for Mar 2024 it was $192.6 million, marking a year-over-year change of. This contributed to the annual value of $192.6 million for FY2023, which is N/A change from last year.
  • Contineum Therapeutics' Preferred Stock Liabilities amounted to $192.6 million in Q1 2024, which was down 0.00% from $192.6 million recorded in Q4 2023.
  • In the past 5 years, Contineum Therapeutics' Preferred Stock Liabilities registered a high of $192.6 million during Q4 2023, and its lowest value of $192.6 million during Q4 2023.
  • For the 2-year period, Contineum Therapeutics' Preferred Stock Liabilities averaged around $192.6 million, with its median value being $192.6 million (2024).